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Abstract
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Objectives—Depression is associated with high healthcare expenditures, and depression
treatment may reduce healthcare expenditures. However, to date, there have not been any studies
on the effect of depression treatment on healthcare expenditures among cancer survivors.
Therefore, this study examined the association between depression treatment and healthcare
expenditures among elderly with depression and incident cancer.
Methods—The current study used a retrospective longitudinal study design, the linked
Surveillance, Epidemiology, and End Results–Medicare database. Elderly (≥66 years) fee-forservice Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, or
prostate cancer (N = 1502) were followed for a period of 12 months after depression diagnosis.
Healthcare expenditures were measured every month for a period of 12-month follow-up period.
Depression treatment was identified during the 6-month follow-up period. The adjusted
associations between depression treatment and healthcare expenditures were analyzed with
generalized linear mixed model regressions with gamma distribution and log link after controlling
for other factors.
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Results—The average 1-year total healthcare expenditures after depression diagnosis were $38
219 for those who did not receive depression treatment; $42 090 for those treated with
antidepressants only; $46 913 for those treated with psychotherapy only; and $51 008 for those
treated with a combination of antidepressants and psychotherapy. As compared to no depression
treatment, those who received antidepressants only, psychotherapy only, or a combination of
antidepressants and psychotherapy had higher healthcare expenditures. However, second-year
expenditures did not significantly differ among depression treatment categories.
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Conclusions—Among cancer survivors with newly diagnosed depression, depression treatment
did not have a significant effect on expenditures in the long term.
Keywords
cancer; expenditures; oncology; SEER-Medicare

1 | Introduction

Author Manuscript

Depression is highly prevalent among cancer survivors, and it has been reported that cancer
survivors with depression incur higher healthcare expenditures as compared to those without
depression.1 Among elderly prostate cancer survivors, those with depression had 33.3%
higher healthcare expenditures during the 12 months after cancer diagnosis as compared to
those without depression.1 Among adults with cancer, those with depression had 31.7%
higher 1-year healthcare expenditures as compared to those without depression.2 While
depression leads to increased healthcare expenditures, depression treatment may lead to a
reduction in healthcare expenditures because of improved health outcomes.

Author Manuscript

However, to date, there have not been any studies that have examined the association
between depression treatment and healthcare expenditures in real-world settings. Therefore,
we infer the association between depression treatment and healthcare expenditures using
findings from studies among elderly individuals. These studies have shown a positive
association between depression treatment and healthcare expenditures. A study among
elderly fee-for-service Medicare beneficiaries with prevalent depression and chronic
physical conditions seeking care in real-world practice settings found that treatment for
depression with antidepressants (20%) and treatment with psychotherapy with/without
antidepressants (29%) was associated with an increase in short-term total healthcare
expenditures.3 A longitudinal study in real-world practice settings found that elderly who
received antidepressant treatment had 32% higher outpatient expenditures as compared to
those without antidepressant treatment.4

Author Manuscript

The abovementioned studies suggest that the relationship between depression treatment and
healthcare expenditures among cancer survivors is not yet established. To the best of our
knowledge, there are no studies that examine whether depression treatment can reduce
healthcare expenditures among cancer survivors seeking care in real-world settings.
Therefore, the primary objective of the current study is to compare healthcare expenditures
by depression treatment categories among elderly fee-for-service Medicare beneficiaries
with newly diagnosed depression and incident breast, colorectal, or prostate cancer. It is
important to understand the association between depression treatment and healthcare
expenditures for many reasons. First, depression is associated with poor health-related
quality of life, higher healthcare utilization and expenditures,1,5 and unplanned
readmissions.6–8 Depression treatment can improve health outcomes and may reduce
healthcare utilization and expenditures. However, in the short term, depression treatment
may lead to higher healthcare cost because of continuous care to treat depression and
fragmented healthcare. Understanding the association between depression treatment and
healthcare cost is particularly important, as a large portion of Medicare healthcare
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expenditures is attributed to the treatment of coexisting health conditions.9 Furthermore,
Medicare has implemented many payment reforms to ensure high-quality care at lower
costs.10 Given the importance of reducing healthcare spending among Medicare
beneficiaries, the current study can provide important information on cost saving of
depression treatment to payers, policy makers, and providers.

2 | Methods
2.1 | Design

Author Manuscript

This study used a retrospective longitudinal study design with a 12-month baseline (April
2006 through December 2011) and a 12-month follow-up period (April 2007 through
December 2012). The baseline period was based on a depression diagnosis date and
consisted of the 12 months before the depression diagnosis date. Healthcare expenditures
were measured every month for a period of 12 months after depression diagnosis. To capture
the variations in healthcare expenditures at different time point of follow-up period, we used
the repeated measures statistical models. As independent measure design often measures
aggregated healthcare expenditures at the follow-up period, repeated measures were used
because it allowed us to capture the expenditures during and after depression treatment.
Depression treatment was measured during the first 6 months after depression diagnosis.
Other explanatory variables were measured during the 12 months before depression
diagnosis and during the follow-up period.
2.2 | Data sources

Author Manuscript

This study used the linked Surveillance, Epidemiology, and End Results (SEER)–Medicare
database files. The SEER Program collects data on all incident cases of cancer that occur in
persons residing in 18 SEER regions.11 Data on all incident cases of cancer, demographic
characteristics, and cancer stage were derived from SEER database. The SEER data have
been linked to Medicare claims files. Medicare claims files consist of inpatient, outpatient,
prescription drug, and other files.
2.3 | Study population
The study population is composed of elderly cancer survivors (age ≥ 66 years) who were
diagnosed with incident breast, colorectal, or prostate cancer and who were newly diagnosed
with depression after cancer diagnosis between 2007 and 2011. We identified the cancer
type (breast, colorectal, or prostate cancer) using the International Classification of Diseases
for Oncology, 3rd Edition histology codes and the primary site variable.

Author Manuscript

2.4 | Cancer survivors with newly diagnosed depression
We identified cancer survivors with newly diagnosed depression on the basis of the National
Committee on Quality Assurance criteria.12 To achieve this, we first established a
depression-free cancer cohort with incident cancer diagnosis between April 2007 and
December 2011. We used a validated algorithm to identify newly diagnosed depression after
cancer diagnosis by including only those who were diagnosed with depression after cancer
diagnosis and who did not have any antidepressant use 90 days prior to depression
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diagnosis.13 We used the following codes from the International Classifications of Diseases,
9th Revision, Clinical Modification: 296.2 (major depressive disorder, single episode), 296.3
(major depressive disorder, recurrent episode), 298.0 (depressive type psychosis), 300.4
(neurotic depression), 309.1 (prolonged depressive reaction), and 311.0 (depressive disorder,
not classified). These codes are widely used to identify depression diagnoses in Medicare
beneficiaries.1,14,15
2.5 | Inclusion/exclusion criteria

Author Manuscript

We required that all individuals have continuous enrollment in Medicare Parts A and B and
no enrollment in Medicare managed care plans during the baseline and follow-up periods.
We also required that individuals have continuous enrollment in Medicare Part D during 3
months prior to and 12 months after depression diagnosis to identify depression treatment in
the follow-up period. We excluded individuals with unknown cancer stage at diagnosis,
those diagnosed through autopsy or death certificate, or those who died during the follow-up
period. Appendix 1.1 summarizes the analytical population selection process. The final
study population consisted of 1502 elderly Medicare beneficiaries with newly diagnosed
depression and incident breast, colorectal, or prostate cancer.
2.6 | Dependent variables

Author Manuscript

2.6.1 | Type and total healthcare expenditures—Healthcare expenditures were
derived from the Medicare claims files and included the amount paid by Medicare. We
identified the type of healthcare expenditure on the basis of whether the services were
provided in an inpatient, outpatient, prescription drug, or home healthcare setting. The
following types of healthcare expenditures were analyzed: inpatient, outpatient, prescription
drugs, and others. Other expenditures consisted of Durable Medical Equipment (DME) and
Home Health Agency (HHA) expenditures. Total healthcare expenditures were derived as
the sum of inpatient, outpatient, prescription drugs, durable medical equipment, and home
health agency expenditures.
Total and type of healthcare expenditures were classified into yearly and monthly
expenditures during the follow-up period. Yearly expenditures consisted of expenditures for
the entire 12-month period after depression diagnosis. Monthly expenditures were calculated
for every month after depression diagnosis. All healthcare expenditures were adjusted by the
consumer price index and expressed in 2012 constant dollars.
2.7 | Key independent variable

Author Manuscript

The key independent variable was the depression treatment during the first 6 months after
depression diagnosis. Antidepressant use was derived from Medicare Part D claims using the
National Drug Codes and generic names. Antidepressants included selective serotonin
reuptake inhibitors, selective norepinephrine reuptake inhibitors, tricyclic antidepressants,
monoamine oxidase inhibitors, and others (mirtazapine and bupropion). Any cancer survivor
with at least one prescription for antidepressants was considered to be using antidepressants.
Psychotherapy visits were derived from Medicare outpatient claims using the Current
Procedural Terminology codes.
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Based on antidepressant use and psychotherapy visits, depression treatment was categorized
into 4 mutually exclusive categories: (1) treatment with antidepressants only: individuals
received, at least, one prescription of antidepressants and no psychotherapy visits; (2)
treatment with psychotherapy only: individuals had, at least, one psychotherapy office visit
and no prescription for antidepressants; (3) both antidepres-sants and psychotherapy:
individuals received, at least, one prescription for antidepressants with at least one
psychotherapy visit; and (4) no treatment: individuals received no antidepressants and no
psychotherapy.
2.8 | Other independent variables

Author Manuscript

2.8.1 | Time-invariant variables—These variables were measured during the baseline
period (ie, 12 months before depression diagnosis). Independent variables included age in
years at cancer diagnosis (66-69, 70-74, 75-79, ≥80) and race (White, African American,
and others), marital status (married, divorced/separated/widowed, and never married), cancer
type (women with breast cancer, women with colorectal cancer, men with colorectal cancer,
and men with prostate cancer), and stage at cancer diagnosis, categorized using the
American Joint Committee on Cancer grouped staging (stage 0/I, stage II, and stage III/IV).
We have also included the number of chronic physical and mental health conditions during
the baseline period, SEER region (Northeast, South, North Central, and West), and the year
of cancer diagnosis. Physical conditions included diabetes, heart disease, hyperlipidemia,
hypertension, stroke, arthritis, osteoporosis, asthma, and chronic obstructive pulmonary
disorder. Mental conditions included Alzheimer and other related disorders, anxiety, and
other mental disorders.

Author Manuscript

2.8.2 | Time-varying independent variables—These were measured every month
during the follow-up period (ie, 12 months after depression diagnosis) and included primary
care physician (PCP) visits and cancer treatment (chemotherapy, radiation therapy, or
surgery).

3 | Statistical Analysis
3.1 | Analyses with repeated measures: short-term healthcare expenditures

Author Manuscript

As healthcare expenditures were measured for every month during the follow-up period,
each individual had 12 observations. These 12 observations were not independent, so
standard regression techniques can not be applied. Therefore, the associations between
depression treatment and total healthcare expenditures were analyzed with a repeated
measure design using generalized linear mixed model (GLMM) regressions with gamma
distribution and log link. The GLMM model was selected because we found that 65% of the
variation in healthcare expenditures was due to differences within individuals. GLMM
regressions account for correlated error terms because of repeated measures from the same
person. In these regressions, all independent variables were included. Based on the
regression coefficient estimates, expenditures associated with depression treatment
categories, as compared to no depression treatment, were calculated.

Psychooncology. Author manuscript; available in PMC 2018 December 01.

Alwhaibi et al.

Page 6

3.2 | Analyses with repeated measures: long-term healthcare expenditures
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We also examined the relationship between depression treatment and long-term expenditures
because it may take time to realize the effects of depression treatment. In these analyses,
long-term healthcare expenditures were derived for each month during the 13- to 24-month
follow-up period. The analyses were restricted to1224 beneficiaries who had continuous feefor-service enrollment in Medicare fee-for-service for 36 months (12 months before
depression diagnosis and 24 months after depression diagnosis). We followed the same
statistical techniques as in the case of short-term healthcare expenditures. We included the
same independent variables as in the short-term healthcare expenditures models.
3.3 | Observed selection bias: adjusting for inverse probability treatment weights

Author Manuscript
Author Manuscript

Inverse probability treatment weights (IPTW) were used to adjust for observed group
differences in depression treatment categories. It is commonly used to balance the
confounders between treatment groups in observational data because treatment groups are
not randomly assigned.16 In our study, observed differences in the healthcare costs between
the depression treatment groups may reflect differences between the group in the observed
covariates rather than effects due to depression treatment. Therefore, we used IPTW to
balance the confounders among depression treatment groups. Inverse probability treatment
weights were calculated using the inverse probability of receiving depression treatment or no
treatment. For each individual, we estimated the predicted probability of receiving
depression treatment categories from a multinomial logistic regression with age, race, sex,
marital status, primary care visits, cancer type, cancer stage, cancer treatment, chronic
conditions, the region of residence, and the year at cancer diagnosis as independent
variables. Then we calculated the adjusted weight for each individual on the basis of the
inverse of their predicted probability to receive depression treatment. Under this approach,
individuals with lower propensity will be upweighted, and those with higher propensity will
be downweighted. This helps balance the probability of treatment across the treatment
groups. To account for the differences in group sizes of the treatment groups, we further
stabilized the weights by dividing them with the sample size of each treatment group.

4 | Results
4.1 | Characteristics of the study population

Author Manuscript

The study population consisted of 1502 elderly fee-for-service Medicare beneficiaries with
incident breast, colorectal, or prostate cancer who had newly diagnosed depression after
cancer diagnosis. In this study population, 45.0% were women with breast cancer, 22.8%
were women with colorectal cancer, 10.1% were men with colorectal cancer, and 22.1%
were men with prostate cancer (Data not presented in tabular form).
4.2 | Description of the study population by depression treatment
Also, we found that 47.4% received antidepressants only, 9.3% received psychotherapy only,
18.9% received both antidepressants and psychotherapy, and 24.4% did not receive any
depression treatment. The description of explanatory variables by depression treatment
categories are presented in Table 1. We found a significantly higher rate of antidepressant
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use among White as compared to African American/others (49.8% vs 36.0%) and a lower
rate of no depression treatment among White as compared to African American/others
(23.1% vs 31.0%). We also observed that individuals in the South region had a significantly
higher rate of antidepressant only use (54.5%), a lower rate of psychotherapy use (5.5%),
and a higher rate of no depression treatment (26.3%).
4.3 | IPTW-adjusted yearly healthcare expenditures by depression treatment categories

Author Manuscript

Table 2 summarizes the average 1-year expenditures for depression treatment categories.
The mean 1-year total healthcare expenditures after depression diagnosis were $38 219 for
those who did not receive depression treatment, $42 090 for those treated with
antidepressants only, $46 913 for those treated with psychotherapy only, and $51 008 for
those treated with a combination of antidepressants and psychotherapy. Average 1-year total
healthcare expenditures were significantly higher for those treated with a combination of
antidepressants and psychotherapy (P value < .001). Also, the average 1-year inpatient and
prescription drug healthcare expenditures after depression diagnosis were significantly
higher for those treated with a combination of antidepressants and psychotherapy (P value
< .001).
4.4 | IPTW-adjusted GLMM of short-term monthly expenditures by depression treatment
categories

Author Manuscript

As compared to no depression treatment, depression treatment with antidepressants only was
associated with a $341 increase in total healthcare expenditures; treatment with
psychotherapy only was associated with a $556 increase while treatment with combination
of antidepressants and psychotherapy was associated with $781 increase. As compared to no
therapy, we found that treatment with antidepressants only, psychotherapy only, and the
combination of antidepressants and psychotherapy was associated with high outpatient
healthcare expenditures (Table 3).
4.5 | IPTW-adjusted GLMM of monthly expenditures by sex
We observed that as compared to men with prostate cancer, women with breast cancer had
$525 higher average monthly total healthcare expenditures. Also, as compare to men with
colorectal cancer, women with colorectal cancer had $205 higher average monthly total
healthcare expenditures. The IPTW-adjusted GLMM of monthly expenditures for other
independent variables are presented in Appendix 1.3.
4.6 | IPTW-adjusted GLMM of long-term monthly expenditures by depression treatment
categories

Author Manuscript

As compared to no depression treatment, we found that treatment with antidepressants only,
psychotherapy only, and the combination of antidepressants and psychotherapy was not
associated with total, inpatient, outpatient, prescription drug, and other healthcare
expenditures (Table 4).
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To ensure robustness of the association between depression treatment categories and
healthcare expenditures, we conducted sensitivity analyses. These included healthcare
expenditures without repeated measures (ie, measuring 1-year healthcare expenditures),
mixed effect linear models with log-transformed healthcare expenditures (Table 3 and
Appendix 1.2), and instrumental variable regressions that controlled for unobserved
selection bias. In the instrumental variable regression, the percentage of psychologists at the
county level was used as an instrument and depression treatment was considered as
endogenous. Across all models and even after controlling for the unobserved selection bias,
depression treatment was associated with higher expenditures as compared to no depression
treatment. For example, depression treatment with psychotherapy only was associated with
higher total healthcare expenditures as compared to no depression treatment in the GLMM
model (β = 0.29; SE = 0.09), the mixed linear model with log-transformed expenditures (β =
0.40; SE = 0.10), the adjusted 1-year healthcare expenditures model (β = 0.31; SE = 0.08),
and the instrumental variable regression model (β = 0.01; SE 0.01).

5 | Discussion

Author Manuscript

The current study examined the association between depression treatment categories and
healthcare expenditures among elderly Medicare beneficiaries with newly diagnosed
depression and incident breast, colorectal, or prostate cancer. To date, the current study is the
first one to analyze the association between depression treatment categories and healthcare
expenditures. We observed that depression treatment categories were associated with higher
short-term healthcare expenditures compared to no depression treatment. However, our
analysis of long-term expenditures indicated that there was no statistically significant
association between depression treatment and expenditures. Taken together, these findings
suggest that it may take time to realize the effects of depression treatment. Our results with
short-term healthcare expenditures are consistent with the 1 published study on depression
treatment and expenditures among elderly with chronic physical conditions, which found
that depression treatment with antidepressants or psychotherapy was associated with an
increase in short-term healthcare expenditures.3 The positive association between depression
treatment and short-term healthcare expenditures was robust and persisted even after
adjustment for other factors and across different model specifications.
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The positive association between depression treatment categories and short-term healthcare
expenditures among cancer survivors has many plausible explanations. Under fee-for-service
healthcare systems, many individuals with both physical and mental health conditions
receive fragmented care and such fragmented care may result in increased expenditures in
the short term. We found lower short-term healthcare expenditures among those with no
depression treatment; future studies may need to compare those who do not receive
treatment to “depression-free” cases to explore whether no depression treatment has
economic consequences. It is also known that adequate depression treatment is critical in
improving health outcomes. A study among adults found that adherence to antidepressant
medication treatment for at least 90 days reduced healthcare expenditures.17
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Our findings have significant policy implications. We estimated the average healthcare
expenditures over a 12-month period among elderly Medicare with newly diagnosed
depression and incident cancer. Therefore, these estimates can be considered as expenditures
following a new episode of depression in elderly with incident cancer. Such estimates have
an important implication for Accountable Care Organization's Medicare Shared Saving
Programs for risk adjustment while also setting the expected expenditure benchmark for
individuals with cancer and newly diagnosed depression. Also, our study findings have
implications for the Centers for Medicare and Medicaid Service's new bundled payment
models as well as a new payment and delivery model, the Oncology Care Model, which
aims to improve the quality of care and care coordination while lowering costs for patients
receiving chemotherapy. Our findings can help these payment models in building the quality
metrics that providers must achieve to maximize their payment.

Author Manuscript

There were other noteworthy findings in the study. We observed racial disparities and
geographical variation in depression treatment. Such racial disparities have been reported
among elderly Medicare beneficiaries.14,18 Studies have attributed the racial disparities in
antidepressant use to cultural factors.19 We observed higher rates of depression treatment in
the Southern region. We can speculate that differences in economic status between South
and other regions of the US may have contributed to these differences.20

Author Manuscript

We observed gender differences in total healthcare expenditures; women with breast cancer
had higher total healthcare expenditures as compared to men with prostate cancer. This is
not surprising as women with breast cancer have a higher cost of cancer care as compared to
other types of cancer 18 and more likely to adhere to antidepressants than men.19 It is also
plausible that there may be gender-specific differences in depression treatment response that
may have contributed to gender differences in expenditures.20 For example, females may not
respond well to some types of antidepressants such as tricyclics.20

Author Manuscript

Our study has many strengths; it is the first that has examined the impact of depression
treatment on total healthcare expenditures in real-world fee-for-service settings. The use of
SEER-Medicare data allowed us to use a longitudinal study design and follow patients for a
long period across different providers. Data from Medicare Part D enabled us to identify
pharmacological therapy for depression and include expenditures related to prescription
drugs. We also tested the robustness of the relationship between depression treatment and
healthcare expenditures using various model specifications. The current study has some
limitations: the SEER-Medicare data are not developed for research purposes and therefore
have limitations associated with its use for estimating total healthcare expenditures. The
study findings cannot be generalized to all Medicare beneficiaries because the study
population is restricted to those residing in SEER regions, those with fee-for-service
Medicare plans, and to elderly Medicare beneficiaries with breast, colorectal, or prostate
cancer. Another limitation related to the observational study was the selection bias; although
we controlled for the observable and unobservable selection bias using the inverse
probability weighting technique and the instrumental variables approach, we cannot
completely eliminate them. We used prescription drug claims, and filling prescriptions may
not always result in use of medications.

Psychooncology. Author manuscript; available in PMC 2018 December 01.

Alwhaibi et al.

Page 10

Author Manuscript

6 | Conclusions
Our study has provided new evidence for the literature on the effect of depression treatment
on healthcare expenditures among elderly fee-for-service Medicare beneficiaries with newly
diagnosed depression and incident breast, colorectal, and prostate cancer seeking care in
real-world clinical practice settings. We found that treatment for depression was associated
with higher short-term healthcare expenditures and was not associated with long-term
healthcare expenditures as compared to no depression treatment. Our findings were robust to
different model specifications, even after adjusting for observed and nonobserved selection
bias. Future studies are needed to replicate and confirm these findings.
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N

186
150
182

70-74

75-79

>80

93

AA/others

155
67
152

Women colorectal

Men colorectal

Men prostate

Psychooncology. Author manuscript; available in PMC 2018 December 01.
155

Stage III/IV

57

No treatment

Yes

644

191

At or after dep. dx

Cardiovascular

464

Bef. dep. dx

Cancer treatment

557

Stage 0/I/II

Cancer stage

338

Women breast

Cancer type

619

White

Race

194

712

66-69

Age in years

Total

47.2

35.8

55.0

46.6

47.1

47.5

45.8

44.4

45.2

50.0

36.0

49.8

44.2

47.9

47.8

50.0

47.4

%

AD Only

120

25

16

98

36

103

27

20

37

55

32

107

47

22

33

37

139

N

8.8

15.7

4.6

9.8

10.9

8.8

8.1

13.2

10.8

8.1

12.4

8.6

11.4

7.0

8.5

9.5

9.3

%

Psych Only

271

38

40

206

58

226

69

27

66

122

53

231

83

62

66

73

284

N

19.9

23.9

11.5

20.7

17.6

19.3

20.8

17.9

19.2

18.0

20.5

18.6

20.1

19.8

17.0

18.8

18.9

%

AD & Psych

329

39

100

228

80

287

84

37

85

161

80

287

100

79

104

84

367

N

24.1

24.5

28.8

22.9

24.3

24.5

25.3

24.5

24.8

23.8

31.0

23.1

24.3

25.2

26.7

21.6

24.4

%

No Therapy

Before IPTW Adjustment

a

c

c

sig

47.9

47.5

48.3

47.7

47.4

47.9

47.7

46.7

47.8

48.1

48.2

47.7

46.3

50.1

47.3

48.2

47.4

Wt%

AD Only

8.8

8.2

8.6

9.1

9.4

8.8

8.3

9.5

9.0

9.0

8.7

8.9

10.0

6.8

9.4

8.8

9.3

Wt%

Psych Only

18.8

20.6

17.7

18.8

18.4

18.9

20.3

18.5

19.8

17.5

18.6

18.8

19.1

18.3

18.5

19.0

18.9

Wt%

AD & Psych

24.4

23.7

25.4

24.4

24.9

24.4

23.8

25.3

23.4

25.3

24.5

24.5

24.6

24.8

24.7

24.0

24.0

Wt%

sig

No Therapy

After IPTW Adjustment

Description of the study population by depression treatment categories before and after inverse probability treatment weights (IPTW)
elderly fee-for-service Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, or prostate cancer SEERMedicare database, 2007-2012
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Author Manuscript
N

634

No

525

No

662

No

228
85
283

South

North Central

West

159

Nonmetro county

%

56.2

45.4

47.1

45.0

54.5

39.5

48.4

37.6

47.7

46.6

48.8

38.4

49.3

N

13

126

54

23

23

39

121

18

116

23

108

31

19

%

4.6

10.3

9.0

12.2

5.5

13.3

8.8

13.5

10.5

5.7

8.3

15.3

13.8

37

247

100

46

57

81

260

24

196

88

219

65

13

N

13.1

20.3

16.6

24.3

13.6

27.6

19.0

18.0

17.8

21.9

16.9

32.0

9.4

%

AD & Psych

74

293

164

35

110

58

326

41

264

103

338

29

38

N

26.1

24.0

27.3

18.5

26.3

19.7

23.8

30.8

24.0

25.7

26.0

14.3

27.5

%

No Therapy

c

c

a

a

c

sig

49.1

47.5

48.4

46.6

48.3

46.6

47.9

46.8

47.8

47.9

47.7

48.7

46.8

Wt%

AD Only

8.8

8.9

8.4

8.3

8.2

11.2

8.9

8.9

9.0

8.7

8.9

9.0

9.6

Wt%

Psych Only

17.6

19.0

19.1

18.0

18.3

19.2

18.8

18.7

19.1

17.8

18.7

19.1

18.0

Wt%

AD & Psych

24.6

24.5

24.1

27.0

25.2

23.0

24.4

25.6

24.1

25.6

24.7

23.2

26.6

Wt%

sig

No Therapy
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P < .001.

c

.001 ≤ P < .01.

b

.01 ≤ P < .05.

a

Abbreviations: AA, African American; AD, antidepressants; Psych, psychotherapy; PTSD, Post Traumatic Stress Disorder; SEER, Surveillance Epidemiology, and End Results; Wt, weighted percentage.
Based on 1502 elderly fee-for-service Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, or prostate cancer who were continuously enrolled in Medicare Parts A and B
during the observation period and Part D during the fol-low-up period. Letters represent significant differences in study population characteristics by depression treatment categories, derived from chi-square
statistics.

553

Metro county

Metro

116

Northeast

Region

50

Yes

Tobacco

187

Yes

Anxiety-PTSD

78

68

Yes

Dementia

No

Psych Only

Author Manuscript
AD Only

Author Manuscript
After IPTW Adjustment

Author Manuscript

Before IPTW Adjustment

Alwhaibi et al.
Page 13

Author Manuscript
TABLE 2

Author Manuscript

Author Manuscript

Author Manuscript
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a

c

sig

4967 (714)

Psych only (N = 94)

3750 (483)

Psych only (N = 136)

40 909 (5330)

Psych only (N = 76)

3821 (513)

3689 (478)

21 985 (3435)

16 934 (1716)

46 289 (4477)

Mean $ (SD) Psych Only (N = 139)

a

c

sig

4760 (605)

Combine AD & Psych (N = 167)

5779 (377)

Combine AD & Psych (N = 284)

40 473 (3928)

Combine AD & Psych (N = 189)

2724 (392)

5779 (375)

26 842 (2692)

15 692 (1345)

51 110 (3508)

Mean $ (SD) Combine AD & Psych (N = 284)

a

c

a

a

c

c

c

sig

3239 (393)

No depression treatment (N = 222)

3333 (249)

No depression treatment (N = 361)

31 420 (2705)

No depression treatment (N = 202)

2053 (247)

3282 (246)

17654 (1772)

15 242 (885)

38 177 (2309)

Mean $ (SD) No Depression Treatment (N =
367)

a
.01 ≤ P < .05.

Letters indicate statistical significances in the average healthcare expenditures by depression treatment categories based on t tests.

Abbreviations: AD, antidepressants; IPTW, Inverse Probability Treatment Weights; Psych, psychotherapy; SEER, Surveillance Epidemiology, and End Results. Based on 1502 elderly fee-for-service
Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, or prostate cancer who were continuously enrolled in Medicare Parts A and B and Part D during the observation
period. Total healthcare expenditures were the sum of inpatient, outpatient, prescription drug, durable medical equipment, and home health agency expenditures. Other expenditures consisted of durable
medical equipment and home health agency.

3981 (484)

AD only (N = 441)

Other expenditures

4747 (306)

AD only (N = 712)

Prescription drugs expenditures

31 867 (3325)

AD only (N = 399)

Inpatient expenditures

Among users

2451 (312)

Other expenditures

4747 (303)

Prescription drugs expenditures

17 961 (2180)

Inpatient expenditures

16 569 (1089)

Outpatient expenditures

41 724 (2841)

Total healthcare exp enditures

Mean $ (SD) AD Only (N = 712)

sig

IPTW-adjusted mean short-term 1-year expenditures by depression treatment categories elderly fee-for-service Medicare beneficiaries with
newly diagnosed depression and incident breast, colorectal, or prostate cancer SEER-Medicare database, 2007-2012
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c

Author Manuscript

b

.001 ≤ P < .01.
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Author Manuscript
Author Manuscript
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Author Manuscript
TABLE 3

Author Manuscript

Author Manuscript

Author Manuscript
0.12a (0.05)
0.17 (0.15)
0.33c (0.08)
0.20 (0.14)

6.17c (0.11)
6.68c (0.26)
5.03c (0.13)
4.58c (0.26)

Outpatient

Inpatient

Prescription drugs

Other

0.37 (0.21)

0.12 (0.12)

0.32 (0.25)

0.21a (0.09)

0.28a (0.13)

Psych Only (SE)

$44

$20

$301

$112

$556

Change#

Mixed linear model with log-transfomed expenditures with IPTW

$21

$59

$150

$63

$341

Change#

0.37c (0.06)
0.16a (0.07)
0.04 (0.06)
0.77c (0.09)
0.09 (0.09)

7.58c (0.16)
7.63c (0.18)
2.76c (0.17)
3.61c (0.22)
1.15c (0.24)

Total

Outpatient

Inpatient

Prescription drugs

Other

9%

77%

4%

16%

37%

% change

0.20 (0.15)

0.07 (0.14)

0.12 (0.09)

0.47c (0.11)

0.40c (0.10)

Psych only (SE)

20%

7%

12%

47%

40%

% change

0.11 (0.12)

0.80c (0.11)

0.21b (0.08)

0.55c (0.09)

0.65c (0.07)

AD & Psych (SE)

0.29 (0.18)

0.57c (0.10)

0.37a (0.16)

0.25c (0.06)

0.38c (0.08)

AD & Psych (SE)

11%

80%

21%

55%

65%

% change

$32

$116

$335

$132

$781

Change#
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Models adjusted for time in months, depression treatment, age, sex, race/ethnicity, marital status, primary care physician visits during each month of follow-up, cancer type, cancer treatment during each
month of follow-up, cancer stage, and number of physical and mental conditions, SEER region, and year of cancer diagnosis. Letters indicate significant differences by depression categories as compared to
no depression treatment based on generalized linear mixed model regressions and mixed linear model regressions on healthcare expenditures.

Percent change in expenditures was calculated by exponentiating the parameter estimate and subtracting 1 (eβ - 1).

Change was calculated by first exponentiating the intercept term to calculate the expenditures for no depression treatment. Then, we exponentiated the sum of the intercept and the parameter estimate for
depression treatment type to get the expenditures for depression treatment. The differences in these two estimates were reported as the change in healthcare expenditures associated with depression
treatment.

#

Abbreviations: AD, antidepressants; IPTW, Inverse Probability Treatment Weights; Psych, psychotherapy; SEER, Surveillance Epidemiology, and End Results. Based on 1502 elderly fee-for-service
Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, or prostate cancer who were continuously enrolled in Medicare Parts A, B, and D during the observation period.
Other expenditures consisted of durable medical equipment and home health agency costs. Total healthcare expenditures consisted of inpatient, outpatient, prescription drug, durable medical equipment, and
home health agency expenditures.

AD only (SE)

Intercept (SE)

Reference Group for Depression Treatment = No depression treatment

0.18a (0.07)

7.45c (0.13)

AD Only (SE)

Total

Intercept (SE)

Generalized Linear Mixed Model with Log Link and Gamma Distribution Reference Group for Depression Treatment = No Depression Treatment

Parameter estimates of depression treatment categories from generalized linear mixed models with IPTW on monthly short-term healthcare
expenditures elderly fee-for-service Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, or prostate
cancer SEER-Medicare database, 2007-2012
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P < .001.
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c

.001 ≤ P < .01.

b

Author Manuscript

a

.01 ≤ P < .05.

Alwhaibi et al.

Author Manuscript
Author Manuscript
Author Manuscript
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TABLE 4

Author Manuscript

Parameter estimates of depression treatment categories from generalized linear mixed
models with IPTW on long-term healthcare expenditures SEER-Medicare database,
2007-2012
Reference Group = No Depression Treatment
Intercept (SE)

AD Only (SE)

Psych Only (SE)

AD & Psych (SE)

Total

4.50c (0.24)

-0.01 (0.13)

0.24 (0.23)

0.19 (0.16)

Outpatient

3.55c (0.28)

-0.16 (0.15)

0.06 (0.26)

0.23 (0.21)

Inpatient

2.20b (0.81)

-0.66 (0.42)

-0.45 (0.57)

-0.38 (0.45)

Prescription drugs

3.64c (0.28)

0.21 (0.13)

0.24 (0.28)

0.30 (0.16)

Other expenditures

0.90 (0.58)

-0.14 (0.30)

0.35 (0.39)

0.22 (0.33)

Author Manuscript

Abbreviations: AD, antidepressants; IPTW, Inverse Probability Treatment Weights; Psych, psychotherapy; SEER, Surveillance Epidemiology, and
End Results. Based on 1224 elderly fee-for-service Medicare beneficiaries with newly diagnosed depression and incident breast, colorectal, or
prostate cancer who were continuously enrolled in Medicare Parts A, B, and D during the 24-month observation period. Other expenditures
consisted of durable medical equipment and home health agency costs. Total healthcare expenditures consisted of inpatient, outpatient, prescription
drug, durable medical equipment, and home health agency expenditures.
Models adjusted for depression treatment, age, sex, race/ethnicity, marital status, primary care physician visits, cancer type, cancer treatment,
cancer stage, and number of physical and mental conditions, SEER region, and year of cancer diagnosis. Letters indicate significant differences by
depression categories as compared to no depression treatment based on generalized linear mixed model regressions on monthly long-term
healthcare expenditures.

a

.01 ≤ P < .05.

b

.001 ≤ P < .01.

c

P < .001.

Author Manuscript
Author Manuscript
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